CN106492048A - A kind of rush sleep preparation and preparation method thereof - Google Patents
A kind of rush sleep preparation and preparation method thereof Download PDFInfo
- Publication number
- CN106492048A CN106492048A CN201710001186.6A CN201710001186A CN106492048A CN 106492048 A CN106492048 A CN 106492048A CN 201710001186 A CN201710001186 A CN 201710001186A CN 106492048 A CN106492048 A CN 106492048A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- glycine
- aminobutyric acid
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 230000007958 sleep Effects 0.000 title claims abstract description 51
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 71
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 42
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 29
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 29
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 29
- 210000000582 semen Anatomy 0.000 claims abstract description 29
- 239000004471 Glycine Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 15
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims description 16
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 230000000147 hypnotic effect Effects 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 9
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229960000796 barbital sodium Drugs 0.000 description 7
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 7
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 229960002275 pentobarbital sodium Drugs 0.000 description 6
- 230000004620 sleep latency Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011715 vitamin B12 Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229960003487 xylose Drugs 0.000 description 4
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003084 Areflexia Diseases 0.000 description 2
- 241000370738 Chlorion Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of promote sleep preparation and preparation method thereof, the sleep preparation functional component that promotees is by Semen Tritici aestivi oligopeptide, gamma aminobutyric acid (GABA), glycine, oligosaccharide and VB12Composition, 20 200 parts of Semen Tritici aestivi oligopeptide, 10 200 parts of gamma aminobutyric acid, 10 200 parts of glycine, 10 100 parts of oligosaccharide, VB based on its parts by weight1215 parts, obtained by mixed method；Described promote the sleep mutual synergism of preparation each component, for hypnotic effect is significant and good in taste, without any side effects；Its preparation method is simple, is suitable for the needs of scale industrial production.
Description
Technical field
The present invention relates to a kind of functional preparation and preparation method thereof, especially a kind of rush sleep preparation and preparation method thereof.
Background technology
With the development of society, operating pressure is big, mood is low or other reasonses cause difficulty falling asleep, Depth of sleep or frequency
Spend short, early awakening and the situation of the insomnia such as the length of one's sleep is not enough or of poor quality happens occasionally, either in adolescence or old
Commonly encountered diseases are all become in people.The bad mental status that can affect daytime of sleep, extended sleep is bad to destroy human immunity
Power, so that cause various diseases.
At this stage generally by taking sleeping pill or medicine containing melatonin is treating insomnia, as medicine has one
Fixed side effect, and insomnia can not be fundamentally solved the problems, such as, therefore need the preparation that a kind of safety has no side effect badly.
Content of the invention
The technical problem to be solved is to provide a kind of rush sleep preparation.
Another technical problem to be solved by this invention is to provide the preparation method that above-mentioned rush sleeps preparation.
For solving above-mentioned technical problem, the technical scheme is that：
A kind of promote sleep preparation, functional component by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, oligosaccharide and
VB12Composition, based on its parts by weight Semen Tritici aestivi oligopeptide 20-200 parts, γ-aminobutyric acid 10-200 part, glycine 10-200 parts,
Oligosaccharide 10-100 parts, VB121-5 parts.
Preferably, above-mentioned rush sleep preparation, Semen Tritici aestivi oligopeptide 100-200 parts, γ-aminobutyric acid based on its parts by weight
50-200 parts, glycine 50-200 parts, oligosaccharide 15-50 parts, VB123-5 parts.
Preferably, above-mentioned rush is slept preparation, based on its parts by weight 200 parts of Semen Tritici aestivi oligopeptide, 200 parts of γ-aminobutyric acid,
200 parts of glycine, 50 parts of oligosaccharide, VB125 parts.
Preferably, above-mentioned rush is slept preparation, and the oligosaccharide is oligomeric xylose, L-arabinose, oligofructose, oligomeric different
Maltose, one kind of hydroxyl isomaltulose or combination in any.
Preferably, above-mentioned rush sleep preparation, can also add appropriate edible or pharmaceutic adjuvant, make tablet, granule
Agent, capsule, oral liquid, solid beverage or liquid beverage etc., the edible or pharmaceutic adjuvant include：Diluent, suspending agent, anti-
Oxidant, emulsifying agent, disintegrating agent, adhesive and/or preservative.
A kind of preparation method for promoting sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, is obtained final product.
Preferably, the preparation method of above-mentioned rush sleep preparation, step (2) gained mixture pass through granulating and forming, spray
Mist is dried to obtain tablet or granule.
Preferably, the preparation method of above-mentioned rush sleep preparation, step (2) gained mixture is by crushing, drying, mistake
Sieve is put in capsule, obtains capsule.
Preferably, the preparation method of above-mentioned rush sleep preparation, adds water to adopt superelevation in step (2) gained mixture
After pressure extraction equipment pressurization pressurize, extracting solution ultrafiltration, concentration, fill are obtained final product.
Above-mentioned rush sleep preparation consumption is 3g/ days.
The invention has the beneficial effects as follows：
Of the present invention promote the sleep mutual synergism of preparation each component, for hypnotic effect is significant, and mouthfeel compared with
Good, without any side effects；Its preparation method is simple, is suitable for the needs of scale industrial production.
Specific embodiment
Technical scheme of the present invention is further described with reference to specific embodiment.
Embodiment 1
A kind of rush sleep preparation, functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, oligofructose
And VB12Composition, wherein, Semen Tritici aestivi oligopeptide 200kg, γ-aminobutyric acid 200kg, glycine 200kg, oligofructose 50kg, VB12
5kg.
The preparation method of above-mentioned rush sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, is obtained final product.
Embodiment 2
A kind of rush sleep preparation, functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, oligomeric wood
Sugar, L-arabinose and VB12Composition, wherein, Semen Tritici aestivi oligopeptide 200kg, γ-aminobutyric acid 10kg, glycine 10kg, oligomeric wood
Sugared 70kg, L-arabinose 30kg, VB125kg.
The preparation method of above-mentioned rush sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, gained mixture obtains tablet by granulating and forming, spray drying.
Embodiment 3
A kind of rush sleep preparation, functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, oligomeric different wheat
Bud sugar and VB12Composition, wherein, Semen Tritici aestivi oligopeptide 20kg, γ-aminobutyric acid 200kg, glycine 200kg, oligomeric isomaltose
10kg、VB121kg.
The preparation method of above-mentioned rush sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, gained mixture is by crushing, drying, sieving is put in capsule, obtains capsule
Agent.
Embodiment 4
A kind of rush sleep preparation, functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, Isomalt ketone
Sugar alcohol and VB12Composition, wherein, Semen Tritici aestivi oligopeptide 200kg, γ-aminobutyric acid 50kg, glycine 50kg, hydroxyl isomaltulose
15kg、VB123kg.
The preparation method of above-mentioned rush sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, the water of 20 times of weight is added in gained mixture, is added with hyperpressure extraction equipment
It is depressed into 300Mpa, pressurize 10 minutes, extracting solution ultrafiltration, concentration, fill are obtained final product.
Embodiment 5
A kind of rush sleep preparation, functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, oligomeric xylose
And VB12Composition, wherein, Semen Tritici aestivi oligopeptide 100kg, γ-aminobutyric acid 200kg, glycine 200kg, oligomeric xylose 50kg,
VB125kg.
The preparation method of above-mentioned rush sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, gained mixture obtains granule by granulating and forming, spray drying.
Embodiment 6
A kind of rush sleep preparation, functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid (GABA), glycine, oligofructose
And VB12Composition, wherein, Semen Tritici aestivi oligopeptide 100kg, γ-aminobutyric acid 40kg, glycine 40kg, oligofructose 20kg, VB12
2kg.
The preparation method of above-mentioned rush sleep preparation, comprises the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, is obtained final product.
Each component in above-described embodiment 1-6：
Semen Tritici aestivi oligopeptide is plant source bioactive peptide, with abundant biological function, such as antioxidation, suppression angiotensin
Invertase activity, opioid activity, immunomodulating etc. are acted on.More importantly Semen Tritici aestivi oligopeptide can improve disappearing for protein in food
Change and utilization, the growth of facilitating digestion tract epithelial cell and enzyme activity, reduce nitric oxide in stomach, increase endogenouss sleep and promote
The generation of material.As the molecular weight of oligopeptide itself is far smaller than protein, is absorbed by the special transhipment passage of intestinal, inhaled
Receive that speed is fast and efficiency high, play plurality of health care functions, therefore compared with protein and aminoacid, with significant advantage.
It is a kind of naturally occurring nonprotein amino acid that γ-aminobutyric acid is (GABA), is mammalian central nervous
Important inhibitory nerve in system passes on material.It is to reduce neuronal activity which acts on, and makes cell hyperpolarization, prevents neural thin
Born of the same parents are overheated.GABA energy bind receptors are simultaneously allowed to activate, and extend the chloride channel open hour, increase Chlorion influx, cause thin
After birth hyperpolarization, now depolarization is more difficult, and neuron is difficult to excitement.Therefore, GABA can be neural with calmness, so as to anxiety,
Reach the effect for improving the health care of sleep.Meanwhile, GABA also has regulation blood pressure and heart rate, resistance to compression brain-strengthening, prevents arteriosclerosis, adjusts fat generation
The other functions such as thank.When GABA lacks in human body, anxiety, uneasiness, the emotion such as tired, worried can be produced.
Glycine is a kind of classificatory non essential amino acid of nontraditional amino acid, take part in protein and important with many
The synthesis of the relevant physiologically active molecule of metabolism, and be a kind of important inhibitory neurotransmitter in central nervous system.Sweet
Propylhomoserin is made Chlorion influx and is induced postsynaptic super by the Glycine Receptors being located at reference to which on postsynaptic neuron film
Change, play its inhibitory action, so as to reduce the irritability of neuron.Before sleeping, intake glycine can pass through to reduce the machines such as body temperature
System significantly improves subjective sleep quality with insomnia tendency.
Oligosaccharide refers to the compound being polymerized containing 2-10 glycosidic bond, connects 2-4 monosaccharide by glycosidic bond
Little aggressiveness is formed, it includes that functional oligose and ordinary oligosaccharide, the common feature of this kind of oligosaccharide are：It is difficult to by gastro-intestinal digestion
Absorb, sugariness is low, and heat is low, does not increase substantially blood glucose and blood fat.Microecological environment in human body can be improved, be conducive to bacillus bifiduss
With the propagation of other probioticss, producing organic acid through metabolism makes intestinal pH reduction, suppression enteral Salmonella and putrefaction bacteria
Growth, adjusts gastrointestinal function, prevents treating constipation, and increases vitamin synthesis, improves immune function of human body etc..
Vitamin B12The vitamin uniquely containing metallic element, by internal organs in antibacterial synthesize, and be present in all
In with animal as the food that originates.Vitamin B12It is stored in liver, but is easy to, by urinating exclusion in vitro, have been used at present
The treatment of asthma, fatigue, hepatitis, insomnia and epilepsy etc., safety and is free from side effects.Vitamin B12It is unique one kind needs
A kind of intestinal secretion thing (castle's intrinsic factor) is helped could absorbed vitamin.Its time of staying in the intestinal is long, takes around
(most of water soluble vitamins only need to several seconds) could be absorbed within three hours.Vitamin B12Main Physiological Function be participate in
Manufacture erythrocyte, prevents pernicious anemia, and additionally aiding prevents nerve injury, maintains fertility, promotes normal growth
Development, and the effect for preventing nerve demyelination.
Above-mentioned each component is commercially available prod, by mutual synergism between each specific components, low especially with Semen Tritici aestivi
It is logical with while utilization, the growth promoter of facilitating digestion tract epithelial cell and enzyme activity that poly- peptide improves the digestion of protein in food
Cross addition γ-aminobutyric acid (GABA) and vitamin B12Effectively improve the health care of sleep, then be aided with the prebioticses such as oligosaccharide, hypnotic
Effect is significant.
Experimental example 1 extends the pentobarbital sodium experiment length of one's sleep
Laboratory animal：Mice is divided into 7 groups by Kunming kind SPF level male mice, 18-22g, below each experiment at random, per
Group 15.Given the test agent gives the time 30 days.
Dosage regimen is shown in Table 1.
Table 1
Determining before experiment makes animal 100% fall asleep, but does not make long pentobarbital sodium dosage (the 40mg/ length of one's sleep
Kg), formally tested with this dosage.
Example weight is weighed, and the sample liquid for 50ml being configured to pure water is used for gavage.0.1ml/10g bw warp is pressed daily
Mouth gavage tested material.
Animal last gives 15min after matched group, test group given the test agent, each group animal lumbar injection pentobarbital sodium
40mg/kg bw, injection volume are 0.1ml/10g bw, and with righting reflex loss as index, whether observation given the test agent can extend penta
The barbital sodium induced hypnotic time.
Data carry out variance analyses with SPSS.
Result of the test is as shown in table 2 below.
Impact of 2 each group of table to the pentobarbital sodium inducing mouse length of one's sleep
Semen Tritici aestivi oligopeptide and γ-aminobutyric acid be applied in combination after experiment knot to the pentobarbital sodium inducing mouse length of one's sleep
Fruit shows：Each test group animal sleep time lengthening, has significant difference, and middle dosage the length of one's sleep compared with positive controls
Effect is more notable, shows that Semen Tritici aestivi oligopeptide and γ-aminobutyric acid combination extend pentobarbital sodium induced hypnotic time test knot
Fruit is the positive.
2 barbital sodium Sleep Latency Test of experimental example
Carry out preliminary experiment before formal test, determining makes animal 100% fall asleep, but do not make the long barbital length of one's sleep
Sodium dosage (200mg/kg), is formally tested with this dosage.Example weight is weighed, and the sample liquid for 50ml being configured to pure water, for filling
Stomach is used.The oral gavage tested materials of 0.1ml/10g bw are pressed daily.
Animal last gives 15min after matched group, test group given the test agent, each group animal lumbar injection barbital sodium, note
The amount of penetrating is 0.1ml/10g bw, with righting reflex loss as index, observes shadow of the given the test agent to barbital sodium Sleep latency
Ring.
Data carry out variance analyses with SPSS.
Result of the test is as shown in table 3 below.
Impact of 3 each group of table to barbital sodium inducing mouse Sleep latency
The reality that Semen Tritici aestivi oligopeptide and γ-aminobutyric acid are affected on barbital sodium inducing mouse Sleep latency after being applied in combination
Test result to show：Each test group dropping asleep latency shortens, and Sleep latency has significant difference with negative control ratio, shows Semen Tritici aestivi
The barbital sodium Sleep latency experimental result of oligopeptide and γ-aminobutyric acid combination is the positive.
The above-mentioned detailed description a kind of rush sleep preparation and preparation method thereof carried out with reference to embodiment, is illustrative
Rather than determinate, several embodiments can be included according to limited scope, therefore without departing from present general inventive concept
Under change and modifications, should belong within protection scope of the present invention.
Claims (8)
1. one kind promotees sleep preparation, it is characterised in that：Functional component is by Semen Tritici aestivi oligopeptide, γ-aminobutyric acid, glycine, oligomeric
Sugar and VB12Composition, Semen Tritici aestivi oligopeptide 20-200 parts, γ-aminobutyric acid 10-200 part, glycine 10-200 based on its parts by weight
Part, oligosaccharide 10-100 parts, VB121-5 parts.
2. according to claim 1 promote sleep preparation, it is characterised in that：Semen Tritici aestivi oligopeptide 100- based on its parts by weight
200 parts, γ-aminobutyric acid 50-200 part, glycine 50-200 parts, oligosaccharide 15-50 parts, VB123-5 parts.
3. according to claim 1 promote sleep preparation, it is characterised in that：Based on its parts by weight 200 parts of Semen Tritici aestivi oligopeptide,
200 parts of γ-aminobutyric acid, 200 parts of glycine, 50 parts of oligosaccharide, VB125 parts.
4. according to claim 1 promote sleep preparation, it is characterised in that：The oligosaccharide is oligomeric xylose, L- Arab
Sugar, oligofructose, oligomeric isomaltose, one kind of hydroxyl isomaltulose or combination in any.
5. one of claim 1-3 described promote sleep preparation preparation method, it is characterised in that：Comprise the following steps that：
(1) each group is weighed by prescription amount be divided into raw material；
(2) each raw material is uniformly mixed, is obtained final product.
6. according to claim 5 promote sleep preparation preparation method, it is characterised in that：Step (2) gained mixes
Thing obtains tablet or granule by granulating and forming, spray drying.
7. according to claim 5 promote sleep preparation preparation method, it is characterised in that：Step (2) gained mixes
Thing is by crushing, drying, sieving is put in capsule, obtains capsule.
8. according to claim 5 promote sleep preparation preparation method, it is characterised in that：Step (2) gained mixes
After water is added in thing using the pressurization pressurize of hyperpressure extraction equipment, extracting solution ultrafiltration, concentration, fill are obtained final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710001186.6A CN106492048A (en) | 2017-01-03 | 2017-01-03 | A kind of rush sleep preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710001186.6A CN106492048A (en) | 2017-01-03 | 2017-01-03 | A kind of rush sleep preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106492048A true CN106492048A (en) | 2017-03-15 |
Family
ID=58345065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710001186.6A Pending CN106492048A (en) | 2017-01-03 | 2017-01-03 | A kind of rush sleep preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106492048A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107594271A (en) * | 2017-08-29 | 2018-01-19 | 安徽生物肽产业研究院有限公司 | A kind of men's health solid beverage |
| CN107737331A (en) * | 2017-11-20 | 2018-02-27 | 中食都庆（山东）生物技术有限公司 | A kind of compound product with tranquilizing effect and preparation method thereof |
| CN109924508A (en) * | 2017-12-16 | 2019-06-25 | 昆山瑞欣健康管理有限公司 | A kind of nutrition and health care complex peptides powder and its preparation method and application |
| CN112056482A (en) * | 2020-10-13 | 2020-12-11 | 广州小象健康产业有限公司 | Sleep-aiding small-molecule peptide solid beverage and preparation method and application thereof |
| CN113423288A (en) * | 2019-02-04 | 2021-09-21 | N·V·努特里奇亚 | Fermented formula containing non-digestible oligosaccharides for sleep improvement |
| CN114190556A (en) * | 2021-12-27 | 2022-03-18 | 华润圣海健康科技有限公司 | Spleen-tonifying and stomach-nourishing food and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784611A (en) * | 2014-01-23 | 2014-05-14 | 云南白药天颐茶品有限公司 | Composition capable of improving sleep and relieving pressure and application thereof |
| CN104738624A (en) * | 2015-03-17 | 2015-07-01 | 鄢明亮 | Nutritional health-care food for neurasthenia, amnesia and insomnia |
| CN104922652A (en) * | 2015-05-18 | 2015-09-23 | 无限极（中国）有限公司 | Application of wheat oligopeptide to preparation of spleen deficiency-improving health-care food or medicine |
| CN105349310A (en) * | 2015-11-23 | 2016-02-24 | 武汉达顺创新科技有限公司 | Brewage method of liquid capable of calming nerves and promoting sleep |
| CN107773609A (en) * | 2016-08-25 | 2018-03-09 | 沈阳药科大学 | It is a kind of that there is the pharmaceutical composition and its preparation for improving sleep function |
-
2017
- 2017-01-03 CN CN201710001186.6A patent/CN106492048A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784611A (en) * | 2014-01-23 | 2014-05-14 | 云南白药天颐茶品有限公司 | Composition capable of improving sleep and relieving pressure and application thereof |
| CN104738624A (en) * | 2015-03-17 | 2015-07-01 | 鄢明亮 | Nutritional health-care food for neurasthenia, amnesia and insomnia |
| CN104922652A (en) * | 2015-05-18 | 2015-09-23 | 无限极（中国）有限公司 | Application of wheat oligopeptide to preparation of spleen deficiency-improving health-care food or medicine |
| CN105349310A (en) * | 2015-11-23 | 2016-02-24 | 武汉达顺创新科技有限公司 | Brewage method of liquid capable of calming nerves and promoting sleep |
| CN107773609A (en) * | 2016-08-25 | 2018-03-09 | 沈阳药科大学 | It is a kind of that there is the pharmaceutical composition and its preparation for improving sleep function |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107594271A (en) * | 2017-08-29 | 2018-01-19 | 安徽生物肽产业研究院有限公司 | A kind of men's health solid beverage |
| CN107737331A (en) * | 2017-11-20 | 2018-02-27 | 中食都庆（山东）生物技术有限公司 | A kind of compound product with tranquilizing effect and preparation method thereof |
| CN109924508A (en) * | 2017-12-16 | 2019-06-25 | 昆山瑞欣健康管理有限公司 | A kind of nutrition and health care complex peptides powder and its preparation method and application |
| CN113423288A (en) * | 2019-02-04 | 2021-09-21 | N·V·努特里奇亚 | Fermented formula containing non-digestible oligosaccharides for sleep improvement |
| CN112056482A (en) * | 2020-10-13 | 2020-12-11 | 广州小象健康产业有限公司 | Sleep-aiding small-molecule peptide solid beverage and preparation method and application thereof |
| CN114190556A (en) * | 2021-12-27 | 2022-03-18 | 华润圣海健康科技有限公司 | Spleen-tonifying and stomach-nourishing food and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106492048A (en) | A kind of rush sleep preparation and preparation method thereof | |
| ES2458353T3 (en) | Preparation comprising amino acids and plants and their activity in alcohol detoxification and in the treatment of migraine | |
| CN107136509A (en) | It is a kind of to be used to improve functional food of immunity and preparation method thereof | |
| CN103520577A (en) | Medicine-and-food dual-purpose preparation for treating pneumoconiosis, clearing away lung-heat and nourishing heart and preparation method for medicine-and-food dual-purpose preparation | |
| CN108339112A (en) | A kind of alimentation composition for promoting wound healing, bedsore reparation, postoperative stress ulcer healing | |
| CN102172383A (en) | Chinese medicinal preparation having functions of enhancing immunity, promoting digestion and improving sleep | |
| CN106578801A (en) | Comprehensive enzyme powder with hypoglycemic effect and preparation method thereof | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN113068833A (en) | Health food with functions of tonifying spleen, eliminating dampness and regulating gastrointestinal tract and preparation method and application thereof | |
| CN103355655A (en) | Composition with alimentary anemia improving function and preparation method of composition | |
| CN101199347A (en) | Pb excluding health care product and its preparation method | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN105028995A (en) | Mixed dog food and preparation method thereof | |
| CN105663204A (en) | Composition and preparation capable of improving immune function, resisting fatigue and treating cold as well as preparation method and application of composition | |
| CN106511740A (en) | Radix ginseng-containing health product and preparation method therefor | |
| CN103845722A (en) | Oligopeptide composition for control of radiation damage or chemotherapy damage and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN116173177A (en) | Pharmaceutical composition for continuously improving male sexual function and preparation method thereof | |
| CN114794478A (en) | Composition capable of reducing blood pressure, blood fat and blood sugar and application thereof | |
| CN108967757A (en) | A kind of thickened red jujube ginger pulp production technology | |
| CN108685101A (en) | Wood frog peptide inulin | |
| CN110269897A (en) | Composition and application thereof that is a kind of antifatigue and improving sleep | |
| KR20010009653A (en) | Composition for treating sexual dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |